Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, and DP Technology announced a strategic cooperation to build a big model platform for biopharmaceutical R&D and a new research paradigm for innovative drug R&D with their respective strengths in the fields of biopharmaceutical R&D and artificial intelligence (AI) big model.

Mabwell has excellent capabilities in ADC technology platform construction and mAb/bsAb drug discovery, and has established the entire industrial chain from R&D to production of ADCs. DP Technology has built a complete micro world cognition and computing system with its independently developed Uni SMART Uni-SMART multimodal science LLM, Uni Mol 3D molecular representation learning LLM, and Uni Fold protein folding LLM, among a series of life science models. The main directions included in the cooperation are:

(1) Knowledge engine construction: Relying on the Uni-SMART multimodal science LLM to build a knowledge engine for R&D of innovative biologics, it realizes accurate and intelligent screening of scientific literature, identifies and extracts multimodal elements, and realizes all-around and in-depth analysis and interpretation, thus constructing a rich and reliable database of targets, significantly improving research efficiency, and accelerating the process of analysis and research and development.

(2) Novel target discovery: RiDYMO® is a hit discovery platform developed by DP Technology. RiDYMO® unlock dynamics of challenging targets and exploring vast chemical space of macrocycles and small molecules with physics. As one of its core algorithms, Reinforced Dynamics (RiD) has a significant advantage in the sampling efficiency of molecular dynamics simulation. By fully leveraging the high-dimensional representation capabilities of neural networks, RiD can efficiently capture dynamic conformational changes in complicated biomolecular systems. The cooperation will combine the advantages of Mabwell's ADC technology and DP technology's RiDYMO® platform to jointly explore breakthroughs in novel target mechanism research and accelerate the discovery of drug molecules from 0 to 1.

Mabwell actively promotes the in-depth integration of biopharmaceuticals and AI technology, and empowers innovative drug R&D. The cooperation will promote the development of biopharmaceuticals from “experiment-driven” to “computation-driven”, further enhance the efficiency of research and development, and bring patients better efficacy and accessibility of innovative biologics to meet the unmet clinical needs in the world.

About DP Technology Co., Ltd.

At DP Technology, we're at the forefront of integrating artificial intelligence into scientific research and industrial R&D. Our "AI for Science" initiative is redefining how we tackle complex scientific challenges, making groundbreaking discoveries more accessible and actionable.

We've developed the "DP Particle Universe," a suite of advanced pre-trained models that seamlessly connect cutting-edge research with real-world industrial applications. Our software suite includes:

- Bohrium® Scientific Computing Space Station
- Hermite® Computational Drug Design Platform
- RiDYMO® Hit Discovery Platform
- Piloteye® Battery Design Automation Platform

Together, these platforms form a robust foundation for industrial innovation and an open ecosystem for AI in science, fostering advancements in key areas such as drug discovery, energy, materials science and information technology.